XNCR late-stage T-cell engager programs advance; pivotal data eyed soon
Session coverage says XNCR is moving its T-cell engager and immunology programs into late-stage development, with pivotal readouts expected at ESMO and in phase II-B UC studies.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.